ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Acasti Pharma Inc

Acasti Pharma Inc (ACST)

2.76
-0.07
(-2.47%)
Closed July 26 4:00PM
2.76
0.00
(0.00%)
After Hours: 6:57PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
2.76
Bid
2.71
Ask
3.05
Volume
10,914
2.69 Day's Range 2.8657
1.72 52 Week Range 3.59
Market Cap
Previous Close
2.83
Open
2.80
Last Trade
85
@
2.86
Last Trade Time
Financial Volume
$ 30,354
VWAP
2.7812
Average Volume (3m)
12,844
Shares Outstanding
9,399,404
Dividend Yield
-
PE Ratio
-0.42
Earnings Per Share (EPS)
-1.37
Revenue
-
Net Profit
-12.85M

About Acasti Pharma Inc

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced effic... Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all which could help to increase treatment compliance and improve patient outcomes. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Quebec City, Quebec, Can
Founded
1970
Acasti Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACST. The last closing price for Acasti Pharma was $2.83. Over the last year, Acasti Pharma shares have traded in a share price range of $ 1.72 to $ 3.59.

Acasti Pharma currently has 9,399,404 shares outstanding. The market capitalization of Acasti Pharma is $26.60 million. Acasti Pharma has a price to earnings ratio (PE ratio) of -0.42.

ACST Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.19-6.44067796612.953.03732.6989962.86293829CS
4-0.08-2.816901408452.843.192.6999822.96216981CS
12-0.28-9.210526315793.043.322.6001128442.93495907CS
260.3715.48117154812.393.592.25193183.115266CS
520.239.090909090912.533.591.72281792.72994774CS
156-0.0774-2.727849439632.837417.63521.724534345.78933575CS
260-9.78-77.99043062212.5418.481.02648556034.11605601CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.57M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
260.07k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.92M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
716.26k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.02M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
408.61M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.33M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.49M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.71M

ACST Discussion

View Posts
makinezmoney makinezmoney 2 years ago
$ACST: Thats good news.... now 0.67

EF Hutton gave them a $2.50 Target.


Hmmmmmmmmmmmmmmmmm



Looking for an entry here


GO $ACST
πŸ‘οΈ0
Eurotradr Eurotradr 2 years ago
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
https://www.acasti.com/en/investors/news-events/press-releases/detail/239/acasti-pharma-announces-preliminary-topline-results-met-all
πŸ‘οΈ0
kzivann kzivann 2 years ago
News. Premarket volume.

ACST
πŸ‘οΈ0
kzivann kzivann 2 years ago
Bid filled @ 88 new low.

ACST
πŸ‘οΈ0
kzivann kzivann 2 years ago
Bid filled @ 88 new low.

ACST
πŸ‘οΈ0
Eurotradr Eurotradr 3 years ago
ACST Acasti Pharma Price Target announced at $6.00 by Oppenheimer. 12/21/20
πŸ‘οΈ0
georgie18 georgie18 3 years ago
ACST...$1.69...Psar flipped Bullish on the second Highest Green Volume Day in the history of ACST...

Chart... https://schrts.co/VuKYQNpa ...
πŸ‘οΈ0
georgie18 georgie18 3 years ago
ACST...$1.64s clearing here...:partying_face:
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
SEC 424B5 > We have entered into a sales agreement with B. Riley Securities, Inc., Oppenheimer & Co. Inc., and H.C. Wainwright & Co., LLC (collectively the β€œAgents” and each an β€œAgent”), relating to the sale of our common shares, no par value per common share, offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offer and sell from time to time our common shares having an aggregate offering price of up to US$75,000,000 through or to the Agents, each acting as sales agent or principal.
πŸ‘οΈ0
Disquisition Disquisition 3 years ago
DUMPED all my shares at 1.40
πŸ‘οΈ0
georgie18 georgie18 3 years ago
ACST...$1.41...in the P/M...plus 27%...:partying_face: https://www.benzinga.com/analyst-ratings/price-target/21/12/24728317/acasti-pharma-shares-spike-higher-after-hours-as-oppenheimer-initiates-coverage-on-s
πŸ‘οΈ0
Disquisition Disquisition 3 years ago
LOADED THE BOAT AT 1.04
πŸ‘οΈ0
Disquisition Disquisition 3 years ago
LOADED MORE AT 1.10
πŸ‘οΈ0
Disquisition Disquisition 3 years ago
LOADED AT 1.16
πŸ‘οΈ0
Disquisition Disquisition 3 years ago
Loaded MORE at 1.20

Let’s do this
πŸ‘οΈ0
Disquisition Disquisition 3 years ago
LOADED THE BOAT at $1.52.

Let’s do this.
πŸ‘οΈ0
Eurotradr Eurotradr 3 years ago
ACST - Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan
Acasti Pharma, Inc.
Wed, October 6, 2021, 8:30 AM

Patents strengthen Acasti’s IP portfolio and provide protection through 2036 and 2037, respectively

LAVAL, Québec, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (β€œAcasti” or the β€œCompany”) (Nasdaq: ACST and TSX-V: ACST), today announces that the European Patent Office, Chinese Patent Office and the Mexican Patent Office have issued composition of matter patents for GTX-101, a novel bio-adhesive film forming topical spray formulation of bupivacaine for the treatment of Postherpetic Neuralgia (PHN). PHN is a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years. GTX-101 could provide significant benefits over the current standard of care including greater convenience, faster onset of action and longer duration of pain relief. The granted patents are valid until 2036.

In addition, the Japanese Patent Office has granted a composition of matter patent for GTX-102, a novel, easy-to-use oral mucosal spray formulation of betamethasone, intended to improve neurological symptoms of Ataxia-telangiectasia (A-T). A-T is a progressive, neurodegenerative genetic disease that primarily affects children causing severe physical disability, for which no treatment currently exists. The granted patent is valid until 2037.

Jan D’Alvise, Chief Executive Officer of Acasti, stated, β€œThese latest patents are important additions to our intellectual property portfolio, expanding product protection to additional important international markets as we continue to progress these drug candidates through clinical studies. We believe these granted composition of matter patents further support the commercial potential of GTX-101 and GTX-102. Both drug candidates have already received Orphan Drug Designation from the FDA and could address important underserved global markets. The goal of these proprietary formulations is to improve the quality of care and patient outcomes by providing significant efficacy, safety and convenience benefits including ease of use, faster onset of action and extended relief.”

https://finance.yahoo.com/news/acasti-pharma-awarded-composition-matter-123000390.html
πŸ‘οΈ0
xLeGenDx xLeGenDx 3 years ago
Loaded $1.98, let’s ??
πŸ‘οΈ0
georgie18 georgie18 3 years ago
ACST...$2.22...Bullish Descent Block Reversal Pattern to the Upside formed on this Oversold Pincher Squeeze set up...imo...we shall see...

Adding here on the post split dip...

Chart... https://schrts.co/rWzDkaBw ...
πŸ‘οΈ0
Monksdream Monksdream 3 years ago
Hard to catch a falling knife.

The price could easily decline below $2. Maybe not today, but over a period of days.
πŸ‘οΈ0
kzivann kzivann 3 years ago
Back in.

ACST
πŸ‘οΈ0
Monksdream Monksdream 3 years ago
You ain't kidding. All the shareholders prior to the reverse split are selling to salvage what they can.
πŸ‘οΈ0
Disquisition Disquisition 3 years ago
INDEFATIGABLE DUMPING
πŸ‘οΈ0
kzivann kzivann 3 years ago
Watch after RS.


ACST
πŸ‘οΈ0
georgie18 georgie18 3 years ago
ACST/ACSTX...$30.40...1/8 Reverse Split...https://www.otcmarkets.com/filing/html?id=15192357&guid=iOP9kW-VfXy9sth

LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (β€œAcasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (β€œGrace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management’s current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D’Alvise as President and Chief Executive Officer, under the oversight of Acasti’s newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and commercial presence in North Brunswick, New Jersey.
πŸ‘οΈ0
kzivann kzivann 3 years ago
Very nice premarket..

ACST
πŸ‘οΈ0
kzivann kzivann 3 years ago
Got some...

ACST
πŸ‘οΈ0
georgie18 georgie18 3 years ago
I am as well...
πŸ‘οΈ0
GREGG THE GREEK GREGG THE GREEK 3 years ago
Still holding a nice position here.


ACST
πŸ‘οΈ0
georgie18 georgie18 3 years ago
ACST...4668...Forming a strong confirmation candle following the Bullish Doji Star on the close from yesterday...imo...we shall see...:partying_face:
πŸ‘οΈ0
GREGG THE GREEK GREGG THE GREEK 3 years ago
Adding some back here.


ACST
πŸ‘οΈ0
georgie18 georgie18 3 years ago
ACST...57...in the P/M...on the Gappa...:partying_face:
πŸ‘οΈ0
Eurotradr Eurotradr 3 years ago
"As part of the Acasti annual and special meeting, Acasti will be seeking the shareholder approvals necessary to complete the merger, elect directors and for other related matters. The 2021 annual and special meeting of Acasti shareholders will be held virtually on August 26, 2021, at 1:00 p.m. (Eastern Time), unless postponed or adjourned to a later date."
πŸ‘οΈ0
Marvy Marvy 3 years ago
When is the merger?
πŸ‘οΈ0
Eurotradr Eurotradr 3 years ago
Premarket looking very nice. Let's see if we can crack $1.00 near term.
πŸ‘οΈ0
Eurotradr Eurotradr 3 years ago
Form S-4/A - https://newsfilter.io/articles/s-4a-form---amend-registration-of-securities-business-combinations---acasti-pharma-inc-0001444192-fi-13bc4f13124dae71b281efeaa56a65fc
πŸ‘οΈ0
GREGG THE GREEK GREGG THE GREEK 3 years ago
ACST
Here we go !!


Nice pop !!!
πŸ‘οΈ0
scooter1ar scooter1ar 3 years ago
watch $AMIH to breakout coming there to
πŸ‘οΈ0
GREGG THE GREEK GREGG THE GREEK 3 years ago
Definitely looks to be shaping up nicely.
Next week. Couple weeks. Whatever.

It’s all good.
In fact. Life is great.

We are blessed to be in the position we’re in.
Where our biggest worry is how soon we’ll bank lol

Have a great weekend !!!


ACST
πŸ‘οΈ0
scooter1ar scooter1ar 3 years ago
Looks like a good week coming next week ,,
πŸ‘οΈ0
GREGG THE GREEK GREGG THE GREEK 3 years ago
Going to get that push again and it's going to be a good one.


ACST
πŸ‘οΈ0
scooter1ar scooter1ar 3 years ago
Buying time on this one
πŸ‘οΈ0
GREGG THE GREEK GREGG THE GREEK 3 years ago
If you're not trading this one around a core, you're missing out on a lot of profits.


Been a great money maker.


ACST
πŸ‘οΈ0
Survivor2012 Survivor2012 3 years ago
https://www.streetinsider.com/dr/news.php?id=18634612&gfv=1
πŸ‘οΈ0
georgie18 georgie18 3 years ago
ACST...5997...:partying_face:
πŸ‘οΈ0
Eurotradr Eurotradr 3 years ago
Let's make some money today. Happy trading!!!
πŸ‘οΈ0
georgie18 georgie18 3 years ago
Gap was at 563 to 573...ACST...5779...in the P/M...Gap filled yesterday...:party:
[8:04 AM]
georgie18 β€” Yesterday at 7:41 AM
ACST...57...in the P/M...Added here in this range...Looking for the .56 dip n rip on the Gap Fill...imo...we shall see...:party:
πŸ‘οΈ0
Eurotradr Eurotradr 3 years ago
Gap at .59 no reason we should not hit that today.
πŸ‘οΈ0
georgie18 georgie18 3 years ago
ACST...57...in the P/M...Added here in this range...Looking for the .56 dip n rip on the Gap Fill...imo...we shall see...
πŸ‘οΈ0
swampboots swampboots 3 years ago
ACST .59, after hours rally?
πŸ‘οΈ0